Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Mesoridazine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Mesoridazine | hsa00040 | Pentose and glucuronate interconversions | 4.00E-02 | 1 | P15121 | AKR1B1 | More | | Mesoridazine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Mesoridazine | hsa00500 | Starch and sucrose metabolism | 2.21E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Mesoridazine | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Mesoridazine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Mesoridazine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Mesoridazine | hsa00600 | Sphingolipid metabolism | 4.77E-02 | 3 | Q9BX95, O14494, P06280 | SGPP1, PLPP1, GLA | More | | Mesoridazine | hsa00620 | Pyruvate metabolism | 3.90E-02 | 2 | P07195, P11766 | LDHB, ADH5 | More | | Mesoridazine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Mesoridazine | hsa00790 | Folate biosynthesis | 2.02E-02 | 1 | P15121 | AKR1B1 | More | | Mesoridazine | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.12E-02 | 1 | P14868 | DARS | More | | Mesoridazine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 6.38E-04 | 3 | P78417, P09211, P11712 | GSTO1, GSTP1, CYP2C9 | More | | Mesoridazine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Mesoridazine | hsa00983 | Drug metabolism - other enzymes | 3.48E-03 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | Mesoridazine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Mesoridazine | hsa01230 | Biosynthesis of amino acids | 2.92E-03 | 5 | P51854, P60891, P05089, P15104, P37837 | TKTL1, PRPS1, ARG1, GLUL, TALDO1 | More | | Mesoridazine | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | | Mesoridazine | hsa01524 | Platinum drug resistance | 1.79E-02 | 2 | O15392, P11388 | BIRC5, TOP2A | More | | Mesoridazine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | Mesoridazine | hsa03010 | Ribosome | 2.25E-04 | 5 | P40429, Q07020, P27635, P05386, P62249 | RPL13A, RPL18, RPL10, RPLP1, RPS16 | More | | Mesoridazine | hsa03013 | RNA transport | 2.12E-02 | 9 | P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | | Mesoridazine | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | | Mesoridazine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Mesoridazine | hsa03060 | Protein export | 4.46E-03 | 2 | Q15070, O76094 | OXA1L, SRP72 | More | | Mesoridazine | hsa03320 | PPAR signaling pathway | 4.33E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | | Mesoridazine | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | | Mesoridazine | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Mesoridazine | hsa04060 | Cytokine-cytokine receptor interaction | 2.05E-02 | 11 | P27930, P14778, P26842, Q13651, P25024, P25025, Q9UBD3, P47992, P09341, P18510, P01730 | IL1R2, IL1R1, CD27, IL10RA, CXCR1, CXCR2, XCL2, XCL1, CXCL1, IL1RN, CD4 | More | | Mesoridazine | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 3.68E-03 | 8 | P09341, P19875, P25024, P25025, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, XCL1, XCL2, IL10RA, IL2RB | More | | Mesoridazine | hsa04062 | Chemokine signaling pathway | 4.11E-04 | 13 | P25024, P25025, P09341, P19875, P47992, Q9UBD3, P07948, P42338, P19174, P63218, P50151, Q08881, P49841 | CXCR1, CXCR2, CXCL1, CXCL2, XCL1, XCL2, LYN, PIK3CB, PLCG1, GNG5, GNG10, ITK, GSK3B | More | | Mesoridazine | hsa04064 | NF-kappa B signaling pathway | 7.48E-05 | 14 | P10415, O00463, P14778, P19174, Q04759, Q9UDY8, Q16548, P07948, P06239, Q13315, P24522, P09341, P19875, Q06643 | BCL2, TRAF5, IL1R1, PLCG1, PRKCQ, MALT1, BCL2A1, LYN, LCK, ATM, GADD45A, CXCL1, CXCL2, LTB | More | | Mesoridazine | hsa04071 | Sphingolipid signaling pathway | 1.82E-04 | 7 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2 | More | | Mesoridazine | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Mesoridazine | hsa04080 | Neuroactive ligand-receptor interaction | 2.16E-03 | 9 | P08311, P28472, Q15722, P21453, Q9H228, O00398, P21730, Q16581, P07550 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, C3AR1, ADRB2 | More | | Mesoridazine | hsa04114 | Oocyte meiosis | 6.23E-03 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Mesoridazine | hsa04115 | p53 signaling pathway | 3.98E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | Mesoridazine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Mesoridazine | hsa04145 | Phagosome | 3.82E-03 | 8 | Q15080, P14598, Q13509, P68371, Q13488, P05164, O60603, P35443 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4 | More | | Mesoridazine | hsa04210 | Apoptosis | 3.77E-02 | 8 | Q13315, P10415, O76075, P24522, Q16548, P43234, P18848, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ATF4, ITPR1 | More | | Mesoridazine | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Mesoridazine | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | | Mesoridazine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | Mesoridazine | hsa04370 | VEGF signaling pathway | 3.06E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Mesoridazine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Mesoridazine | hsa04610 | Complement and coagulation cascades | 1.47E-05 | 2 | P00734, P0C0L4 | F2, C4A | More | | Mesoridazine | hsa04612 | Antigen processing and presentation | 2.09E-04 | 8 | P13765, P48382, Q14953, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Mesoridazine | hsa04613 | Neutrophil extracellular trap formation | 2.18E-03 | 7 | P04908, Q93077, P62807, O60814, P68431, O43315, Q16539 | H2AC4; H2AC8, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | | Mesoridazine | hsa04640 | Hematopoietic cell lineage | 1.48E-04 | 12 | P13612, P14778, P27930, P11215, P11836, P25063, P07766, P09693, P01732, P01730, P09564, P13765 | ITGA4, IL1R1, IL1R2, ITGAM, MS4A1, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB | More | | Mesoridazine | hsa04650 | Natural killer cell mediated cytotoxicity | 9.30E-08 | 17 | P16298, P50591, P19174, P01375, P78314, P06239, O60880, P20963, P42338, Q02750, Q13241, P26718, O14931, O75015, P26717, Q14953, P26715 | PPP3CB, TNFSF10, PLCG1, TNF, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, MAP2K1, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q6PCB7 | SLC27A1 | Long-chain fatty acid transport protein 1 | P16298 | PPP3CB | Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform | 0.774 | Q6PCB7 | SLC27A1 | Long-chain fatty acid transport protein 1 | P50591 | TNFSF10 | Tumor necrosis factor ligand superfamily member 10 | 0.9 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.807 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.835 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.799 | Q13547 | HDAC1 | Histone deacetylase 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.786 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.823 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | Q6PCB7 | SLC27A1 | Long-chain fatty acid transport protein 1 | Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 0.799 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.733 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.807 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.888 | Q13547 | HDAC1 | Histone deacetylase 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.772 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | Q13547 | HDAC1 | Histone deacetylase 1 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.735 | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.712 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 |
| Mesoridazine | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | | Mesoridazine | hsa04658 | Th1 and Th2 cell differentiation | 1.52E-09 | 13 | Q04759, P07766, P20963, P09693, Q16539, P19174, P01730, P06239, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, CD4, LCK, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Mesoridazine | hsa04659 | Th17 cell differentiation | 1.42E-07 | 13 | Q04759, Q16539, P19174, P01730, P06239, P14784, P13765, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, MAPK14, PLCG1, CD4, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | | Mesoridazine | hsa04660 | T cell receptor signaling pathway | 3.47E-07 | 14 | Q04759, P42338, O95267, Q08881, P19174, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | PRKCQ, PIK3CB, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Mesoridazine | hsa04662 | B cell receptor signaling pathway | 2.57E-02 | 5 | P49841, P60033, P07948, P21854, Q8N149 | GSK3B, CD81, LYN, CD72, LILRA2 | More | | Mesoridazine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | Mesoridazine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Mesoridazine | hsa04720 | Long-term potentiation | 2.85E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | Mesoridazine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Mesoridazine | hsa04725 | Cholinergic synapse | 4.83E-02 | 4 | P22694, Q14643, P18848, P10415 | PRKACB, ITPR1, ATF4, BCL2 | More | | Mesoridazine | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | Mesoridazine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Mesoridazine | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Mesoridazine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Mesoridazine | hsa04914 | Progesterone-mediated oocyte maturation | 1.00E-02 | 4 | Q17RY0, Q9Y6D9, P51812, Q02750 | CPEB4, MAD1L1, RPS6KA3, MAP2K1 | More | | Mesoridazine | hsa04915 | Estrogen signaling pathway | 2.96E-02 | 5 | P14780, P22694, P18848, Q14643, P10415 | MMP9, PRKACB, ATF4, ITPR1, BCL2 | More | | Mesoridazine | hsa04918 | Thyroid hormone synthesis | 3.50E-02 | 3 | P22694, P18848, Q14643 | PRKACB, ATF4, ITPR1 | More | | Mesoridazine | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Mesoridazine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | Mesoridazine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Mesoridazine | hsa04927 | Cortisol synthesis and secretion | 4.44E-04 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | | Mesoridazine | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.13E-02 | 5 | Q14643, P22694, P23771, P18848, P10415 | ITPR1, PRKACB, GATA3, ATF4, BCL2 | More | | Mesoridazine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | Mesoridazine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Mesoridazine | hsa04961 | Endocrine and other factor-regulated calcium reabsorption | 2.68E-02 | 3 | P20020, Q9UEF7, P17252 | ATP2B1, KL, PRKCA | More | | Mesoridazine | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | Mesoridazine | hsa04972 | Pancreatic secretion | 2.68E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | | Mesoridazine | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Mesoridazine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | Mesoridazine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | Mesoridazine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | Mesoridazine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Mesoridazine | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Mesoridazine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 5.40E-05 | 7 | Q16539, P09341, P19875, P19174, P25024, P25025, P07948 | MAPK14, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2, LYN | More | | Mesoridazine | hsa05132 | Salmonella infection | 4.62E-03 | 11 | P51617, Q9UJU2, Q13546, Q13489, P10415, O75369, O60603, Q9BQS8, Q13561, Q13509, P68371 | IRAK1, LEF1, RIPK1, BIRC3, BCL2, FLNB, TLR2, FYCO1, DCTN2, TUBB3, TUBB2C | More | | Mesoridazine | hsa05133 | Pertussis | 2.95E-03 | 2 | P0DP23, P0C0L4 | CALM1, C4A | More | | Mesoridazine | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Mesoridazine | hsa05135 | Yersinia infection | 2.59E-03 | 10 | Q05397, P51812, P13612, P06239, Q16539, Q02750, P49841, Q96JJ3, P01730, P01732 | PTK2, RPS6KA3, ITGA4, LCK, MAPK14, MAP2K1, GSK3B, ELMO2, CD4, CD8A | More | | Mesoridazine | hsa05143 | African trypanosomiasis | 3.01E-03 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | Mesoridazine | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | | Mesoridazine | hsa05146 | Amoebiasis | 2.05E-05 | 11 | P09341, P19875, P14778, P27930, P01375, P42338, P11215, P05089, P30679, P22694, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1 | More | | Mesoridazine | hsa05152 | Tuberculosis | 1.08E-02 | 8 | Q13488, P48382, P25208, O60603, P10415, P01568, Q9UDY8, P51617 | TCIRG1, RFX5, NFYB, TLR2, BCL2, IFNA21, MALT1, IRAK1 | More | | Mesoridazine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Mesoridazine | hsa05163 | Human cytomegalovirus infection | 8.17E-03 | 9 | P63218, P50151, P49841, P14778, Q13651, P25025, Q16539, O00463, P30101 | GNG5, GNG10, GSK3B, IL1R1, IL10RA, CXCR2, MAPK14, TRAF5, PDIA3 | More | | Mesoridazine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 3.96E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | | Mesoridazine | hsa05169 | Epstein-Barr virus infection | 1.68E-03 | 12 | P13765, Q13547, O00463, Q16539, P07948, P30101, Q13761, P24522, P29728, P07766, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, MAPK14, LYN, PDIA3, RUNX3, GADD45A, OAS2, CD3E, CD3G, CD247 | More | | Mesoridazine | hsa05170 | Human immunodeficiency virus 1 infection | 2.65E-03 | 19 | P62873, P63218, P50151, P17252, Q13546, O00463, P30101, Q14643, P01568, P01730, Q16539, P51617, O60603, Q13315, P07766, P09693, P20963, P10415, Q9Y6Q5 | GNB1, GNG5, GNG10, PRKCA, RIPK1, TRAF5, PDIA3, ITPR1, IFNA21, CD4, MAPK14, IRAK1, TLR2, ATM, CD3E, CD3G, CD247, BCL2, AP1M2 | More | | Mesoridazine | hsa05171 | Coronavirus disease - COVID-19 | 3.87E-04 | 5 | P62249, P40429, P27635, Q07020, P05386 | RPS16, RPL13A, RPL10, RPL18, RPLP1 | More | | Mesoridazine | hsa05202 | Transcriptional misregulation in cancer | 9.36E-04 | 16 | Q12778, Q15532, Q13315, P14780, P14923, Q15744, Q16548, Q13489, Q13077, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P24522 | FOXO1, SS18, ATM, MMP9, JUP, CEBPE, BCL2A1, BIRC3, TRAF1, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | | Mesoridazine | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Mesoridazine | hsa05204 | Chemical carcinogenesis | 1.09E-03 | 3 | P09211, P78417, P11712 | GSTP1, GSTO1, CYP2C9 | More | | Mesoridazine | hsa05205 | Proteoglycans in cancer | 2.02E-03 | 12 | Q13009, Q14643, O75369, P14780, P17252, O60603, P01375, P23588, P04628, Q13635, P22694, P08962 | TIAM1, ITPR1, FLNB, MMP9, PRKCA, TLR2, TNF, EIF4B, WNT1, PTCH1, PRKACB, CD63 | More | | Mesoridazine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.65E-05 | 10 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, Q04759, Q16539, P01730 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, PRKCQ, MAPK14, CD4 | More | | Mesoridazine | hsa05321 | Inflammatory bowel disease | 1.19E-03 | 6 | P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | | Mesoridazine | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Mesoridazine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Mesoridazine | hsa05332 | Graft-versus-host disease | 1.91E-05 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | | Mesoridazine | hsa05340 | Primary immunodeficiency | 3.99E-02 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | | Mesoridazine | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | |